Categories Earnings, Health Care

Amarin (AMRN) maintains revenue growth despite COVID-19 headwinds

Patient visits dropped by around 70% from pre-COVID-19 levels

Amarin Corporation plc (NASDAQ:AMRN) reported second quarter 2020 earnings results today. The company reported a 34% growth in total revenue to $135.3 million, helped by a 33% growth in net product revenue.

Net product revenues rose to $133.7 million, mainly due to higher VASCEPA sales and an increase in VASCEPA selling price in the US, reflecting various factors like managed care coverage improvements. International sales of VASCEPA totaled $1.8 million in the quarter.

On a GAAP basis, net income totaled $4.4 million, or $0.01 per share, compared to a net loss of $1.8 million, or $0.01 per share, in the same period last year. Adjusted net income was $16.5 million, or $0.04 per share, compared to $6.1 million, or $0.02 per share, last year.

Normalized prescriptions for VASCEPA increased by approx. 44% and 47% year-over-year in the second quarter based on data from Symphony Health and IQVIA, respectively. Estimated normalized VASCEPA prescriptions totaled around 1,090,000 and 1,007,000, based on data from Symphony and IQVIA.

Revenue and prescription growth for VASCEPA were negatively impacted by the restrictions put in place due to the coronavirus pandemic, which led to reductions in patient visits, routine lab tests and interactions between sales personnel and physicians. According to reports from IQVIA, patient visits dropped by around 70% from pre-COVID-19 levels.

In a separate release, Amarin announced its plans to launch VASCEPA in Europe through its own commercial organization for the reduction of cardiovascular risk in high-risk patients. The application is in the late stages of review and is awaiting approval from European regulatory agencies.

The company also expects the results from its VASCEPA clinical trial in China to be reported by its partner before the end of 2020.

Looking for more insights on the earnings results? Click here to access the full transcripts of the latest earnings conference calls!

Most Popular

AVGO Earnings: Highlights of Broadcom’s Q4 2022 report

Chipmaker Broadcom, Inc. (NASDAQ: AVGO) Thursday reported better-than-expected earnings and revenues for the fourth quarter of 2022. Net profit was $10.45 per share in the final three months of the

COST Earnings: All you need to know about Costco Wholesale Corporation’s Q1 2023 earnings results

Costco Wholesale Corporation (NASDAQ: COST) reported first quarter 2023 earnings results today. Net sales increased 8.1% to $53.44 billion compared to the same period a year ago. Comparable sales were up

Three factors that bode well for Campbell Soup (CPB) in the current environment

Shares of Campbell Soup Company (NYSE: CPB) were up 1% on Thursday. The stock has gained 30% year-to-date and 34% over the past 12 months. The food company started the

Add Comment
Loading...
Cancel
Viewing Highlight
Loading...
Highlight
Close
Top